National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 1146686

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 4/30/2021

VAERS ID: 1146686
VAERS Form:2
Age:49.0
Sex:Female
Location:Maryland
Vaccinated:2021-03-18
Onset:2021-03-18
Submitted:0000-00-00
Entered:2021-03-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / 1 RA / OT

Administered by: Unknown      Purchased by: ??
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Paraesthesia, Vaccination site inflammation

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: No adverse event (No medical history reported)
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': USMODERNATX, INC.MOD20210

Write-up: Guillain-barre syndrome; Inflammation at the injection site; Tingling and numbness now spread to her finger tips; Tingling and numbness now spread to her finger tips; This spontaneous report was reported by a physician concerning a 49-years-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) and experienced Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips. The patient''s medical history was not provided. Concomitant product use was not provided by the reporter. On 18 Mar 2021, prior to onset of the events, the patient received first of two planned doses of mRNA-1273 (lot/batch number: unknown) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 18 Mar 2021, the patient experienced inflammation at the injection site, tingling and numbness now spread to her fingertips and might be developing medically significant event of Guillain-Barre syndrome. On 19 Mar 2021, increasing severity of tingling and numbness. Treatment for the events included ibuprofen. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips was not reported.; Reporter''s Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested.


Changed on 5/7/2021

VAERS ID: 1146686 Before After
VAERS Form:2
Age:49.0
Sex:Female
Location:Maryland
Vaccinated:2021-03-18
Onset:2021-03-18
Submitted:0000-00-00
Entered:2021-03-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / 1 RA / OT

Administered by: Unknown      Purchased by: ??
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Paraesthesia, Vaccination site inflammation

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: No adverse event (No medical history reported)
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': USMODERNATX, INC.MOD20210

Write-up: Guillain-barre syndrome; Inflammation at the injection site; Tingling and numbness now spread to her finger tips; Tingling and numbness now spread to her finger tips; This spontaneous report was reported by a physician concerning a 49-years-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) and experienced Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips. The patient''s medical history was not provided. Concomitant product use was not provided by the reporter. On 18 Mar 2021, prior to onset of the events, the patient received first of two planned doses of mRNA-1273 (lot/batch number: unknown) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 18 Mar 2021, the patient experienced inflammation at the injection site, tingling and numbness now spread to her fingertips and might be developing medically significant event of Guillain-Barre syndrome. On 19 Mar 2021, increasing severity of tingling and numbness. Treatment for the events included ibuprofen. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips was not reported.; Reporter''s Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested.


Changed on 5/21/2021

VAERS ID: 1146686 Before After
VAERS Form:2
Age:49.0
Sex:Female
Location:Maryland
Vaccinated:2021-03-18
Onset:2021-03-18
Submitted:0000-00-00
Entered:2021-03-30
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / 1 RA / OT

Administered by: Unknown      Purchased by: ??
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Paraesthesia, Vaccination site inflammation

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: No adverse event (No medical history reported)
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': USMODERNATX, INC.MOD20210

Write-up: Guillain-barre syndrome; Inflammation at the injection site; Tingling and numbness now spread to her finger tips; Tingling and numbness now spread to her finger tips; This spontaneous report was reported by a physician concerning a 49-years-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) and experienced Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips. The patient''s medical history was not provided. Concomitant product use was not provided by the reporter. On 18 Mar 2021, prior to onset of the events, the patient received first of two planned doses of mRNA-1273 (lot/batch number: unknown) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 18 Mar 2021, the patient experienced inflammation at the injection site, tingling and numbness now spread to her fingertips and might be developing medically significant event of Guillain-Barre syndrome. On 19 Mar 2021, increasing severity of tingling and numbness. Treatment for the events included ibuprofen. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events Guillain-Barre syndrome, inflammation at the injection site and tingling and numbness now spread to her finger tips was not reported.; Reporter''s Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested.

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1146686&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166